Literature DB >> 35424560

A multi pathway coupled domino strategy: I2/TBHP-promoted synthesis of imidazopyridines and thiazoles via sp3, sp2 and sp C-H functionalization.

Yishou Wang1, Shichen Li1, Xinfeng Wang1, Yiming Yao1, Lei Feng1, Chen Ma1.   

Abstract

I2/TBHP-promoted, one-pot, multi pathway synthesis of imidazopyridines and thiazoles has been achieved through readily available ethylarenes, ethylenearenes and ethynearenes. I2/TBHP as an initiator and oxidant is used to realize the C-H functionalization of this domino reaction. Simple and available starting materials, wide range of functional group tolerance, high potential for drug activity of the products and application in production are the advantageous features of this method. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2022        PMID: 35424560      PMCID: PMC8981869          DOI: 10.1039/d1ra07438e

Source DB:  PubMed          Journal:  RSC Adv        ISSN: 2046-2069            Impact factor:   3.361


Introduction

Nitrogen- and sulfur-containing heterocyclic scaffolds generally exhibit biological activities such as anti-inflammatory,[1] anticancer,[1] antibacterial,[1] antiviral[1] or signal conditioning activity.[1] Such scaffolds can be found in many drug skeletons and natural products.[2] For example, zolimidine, zolpidem, olprinone and saripidem are commercialized drugs, and YM-11124 and amiphenazole play an important signal regulation role in life activities.[3] Therefore, exploring and developing new methods of synthesizing these compounds has very important commercial and application value (Scheme 1).
Scheme 1

The drugs and biologically active compounds containing imidazopyridines or thiazoles units.

To date, there are many ways to synthesize imidazole or thiazole rings. In general, the usual synthetic strategy is the direct condensation and cyclization of α-halo acetophenone and 2-aminopyridine (scheme 2a).[4] Alternatively, acetophenone as a raw material, first completes the ortho-halogenation of the carbonyl group, and then condenses and cyclizes with 2-aminopyridine (Scheme 2b).[5] In recent years, some new synthetic methods have been developed. For instance, when ethylbenzene[6] and styrene[7] act as starting materials, α-halo acetophenone is synthesized by adding an oxidant and a halogenating reagent (Scheme 2c and d). In addition, transition metal-catalyzed C–H bond activation methods for phenylacetylene[8] have been reported (Scheme 2e).
Scheme 2

Approach for the synthesis of imidazo[1,2-a]pyridine and thiazole.

In the literature reported in the past, α-bromo acetophenone has been used more often, and the reaction of α-bromo acetophenone is more mature.[9] But α-bromo acetophenone, as a chemical weapon used for tearing, can cause great harm to our scientific researchers and the environment.[10] Iodine compounds have better reactivity due to the easy removal of iodine, the reaction process is milder and greener, and the post-reaction treatment is also simple and convenient. Meanwhile, it is rare that ethylbenzene is directly functionalized as a raw material. Styrene mainly reacts by the addition of unsaturated bonds. Phenylacetylene yields the corresponding products through the coordinated activation of acetylene bonds by transition metals. While the reaction systems were not been reported which were simultaneously suitable for ethylbenzene, styrene and phenylacetylene. This has application value in the petrochemical industry, because the boiling points of ethylbenzene, styrene, and phenylacetylene are similar (136–145 °C). Their mixtures are widely present in industrial production,[11] for example, the process of cracking of petroleum and the process of dehydrogenating ethylbenzene to synthesize styrene.[12] The fact means that the system suitable for ethylbenzene, styrene and phenylacetylene has very cheap and readily available raw materials in practical applications. In this context, we developed a strategy that is applicable to them. This strategy can be used to synthesize imidazopyridines and thiazoles in one pot, and the source of raw materials is wide. α-Iodo acetophenone is an intermediate in this system, which means it is more environmentally friendly. We also explored the mixed-amplified experiment of the system, which proves it has potential industrial application value. We chose ethylbenzene and 2-aminopyridine as standard substrates to screen the most suitable reaction conditions (Table 1). The product 3aa was obtained with a yield of 36% when CuI was used as a catalyst (entry 1). First, we studied the influence of different iodine sources on the reaction yield. When no iodine source, the target product can not be obtained, which proved iodine source necessary in the reaction process (entry 2). When N-iodosuccinimide (NIS), tetrabutylammonium iodide (TBAI) and KI were involved in the system, only trace products were formed (entry 3, 4 and 5). I2 was used as the iodine source, the product was obtained with a considerable yield of 76% (entry 6). The oxidant was also crucial for this reaction. When Na2S2O8, dibenzoyl peroxide (BPO) and O2 were used as oxidant in the reaction system, the yield of the product was 57%, 65% and a trace (entry 7, 8 and 9). Experiments showed that tert-butyl hydroperoxide (TBHP) is a better oxidant in the reaction system (entry 6). Then, the catalyst was optimized and screened. When no catalyst, the target product can be obtained with a yield of 30% (entry 10). When NH4Cl and FeCl3 was added, the yield of the product was 27% and 34% (entry 11 and 12). The product can not be obtained when AlCl3 and K2CO3 were used as catalysts (entry 13 and 14). Other transition metal salts also were involved as catalysts, such as Cu(OAc)2 and AgNO3, and the yield of 3aa was not as good as when CuCl2 was used (entry 15 and 16). Then, we tried different solvents and found DMF was best (entry 17, 18 and 19). Finally, we determined that in the presence of I2 (0.4 eq.), TBHP (3.0 eq.) and CuCl2 (0.5 eq.), DMF as solvent, the product was obtained with a yield of 82%.

Optimization of the reaction conditionsa

Entry[I][O]CatalystSolventYieldb, %
1CuITBHPDMSO36
2TBHPCuCl2DMSONone
3NISTBHPCuCl2DMSOTrace
4TBAITBHPCuCl2DMSOTrace
5KITBHPCuCl2DMSOTrace
6I2TBHPCuCl2DMSO76
7I2Na2S2O8CuCl2DMSO57
8I2BPOCuCl2DMSO65
9I2O2CuCl2DMSOTrace
10I2TBHPDMSO30
11I2TBHPNH4ClDMSO27
12I2TBHPFeCl3DMSO34
13I2TBHPAlCl3DMSONone
14I2TBHPK2CO3DMSONone
15I2TBHPCu(OAc)2DMSO52
16I2TBHPAgNO3DMSO54
17I2TBHPCuCl2DCE65
18 I 2 TBHP CuCl 2 DMF 82
19I2TBHPCuCl2MeCN78

Reaction conditions: 1a (1 mmol), [I] (0.4 mmol), [O] (3 mmol), 120 °C, 1 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h.

Isolated yield.

Reaction conditions: 1a (1 mmol), [I] (0.4 mmol), [O] (3 mmol), 120 °C, 1 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h. Isolated yield. After determining the optimal reaction conditions, we explored the scope and limitations of this transformation by using substituted ethylarenes (Table 2). We found both the electron-deficient and electron-rich ethylarenes were suitable substrates to provide the desired products in moderate to excellent yields (3aa–3ea, 3ia–3ka). This proved that the reaction has a wide range of application to ethylarenes connected with various groups. The reaction had a higher yield when the ethylarenes had a larger conjugated structure (3ca, 3fa, 3ia). Meanwhile, substrates with large steric hindrance like 2-methyl ethylbenzene and 1,2-diphenylethane were also tolerant to this reaction to afford the desired products in moderate yields (3ba, 3ga). It was worth mentioning that 3ha zolimidine can also be synthesized by this reaction with a relatively good yield. Zolimidine is a common gastroprotective drug which was used to treat stomach ulcers and gastroesopha geal reflux disease. Excitingly, heteroarylethanes such as 2-ethylfuran and 2-ethylthiophene were also suitable for this reaction, and the products were obtained with relatively good yields (3la, 3ma). The scope of 2-aminopyridines was also studied. To our satisfaction, when electron-donating and electron-withdrawing groups substituted 2-aminopyridines were subjected to this reaction, the corresponding products (3ab–3ai) were isolated in 57–75% yields. To our delight, structures with carbon–sulfur unsaturated double bonds like thiourea and benzothioamide, thiazole hybrid structures like α-aminothiazole were also suitable for this reaction system, and the target products (3aj–3al) were furnished with good yields.

Substrate scope of various ethylarenes and 2-aminopyridinesa

Reaction conditions: 1a (1 mmol), I2 (0.4 mmol), TBHP (3 mmol), 120 °C, 1 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h.

Reaction conditions: 1a (1 mmol), I2 (0.4 mmol), TBHP (3 mmol), 120 °C, 1 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h. Having obtained encouraging results with ethylarenes, we turned our attention to C–H functionalization of ethylenearenes followed C–N bond construction coupling with 2-aminopyridines (Table 3). Excitingly, under optimized conditions, the corresponding product (3aa) can be obtained with a yield of 79%. Furthermore, whether styrenes were attached with electron-rich group such as –Me, or attached with electron-withdrawing groups such as –NO2 and –Cl at the meta or para positions, the corresponding products can be obtained in good yields (3ca–3na). The heterocycles, such as 2-bromo thiophene, did not affect the overall efficiency, and the corresponding products 3oa were furnished in moderate yields. 2-Aminopyridines with halogen (5-Br, 4-Br), electron-deficient (5-COOMe), and electron-rich (4-OMe) groups reacted smoothly to afford the corresponding products (3ag–3an) in moderate to good yields. Finally, as expected, both benzothioamide and 2-aminothiazole were tolerant to this system, and the corresponding products (3ak, 3al) can be obtained with good yields.

Substrate scope of various ethylenearenes and 2-aminopyridinesa

Reaction conditions: 1a (1 mmol), I2 (0.4 mmol), TBHP (3 mmol), 120 °C, 1–1.5 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h.

Reaction conditions: 1a (1 mmol), I2 (0.4 mmol), TBHP (3 mmol), 120 °C, 1–1.5 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h. With results of ethylarenes and ethylenearenes in hand, we tried the C–H functionalization of phenylacetylene and then reacted with 2-aminopyridines under the optimal reaction conditions (Table 4). Excitingly, 3aa was provided with a yield of 74%. The substituted phenylacetylene (4-Me) afforded the corresponding imdazo[1,2-a]pyridine in good yield. Meanwhile, substrates with large steric hindrance like 2-trifluoromethyl phenylacetylene was also tolerant to this reaction to afford 3pa in moderate yields. The fluorine groups on different substitution positions (2-F, 3-F, 4-F) reacted smoothly to afford the corresponding products (3ea, 3qa, 3ra) in moderate to good yields. Finally, when nitrile or phenyl substituted 2-aminopyrides were subjected to this reaction, the corresponding products (3ao, 3ap) were isolated in good yields. Thiourea also can react to get 3aj in 76% yield.

Substrate scope of various ethynearenes and 2-aminopyridinesa

Reaction conditions: 1a (1 mmol), I2 (0.4 mmol), TBHP (3 mmol), 120 °C, 1–1.5 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h.

Reaction conditions: 1a (1 mmol), I2 (0.4 mmol), TBHP (3 mmol), 120 °C, 1–1.5 h then 2-aminopyridine (2.0 mmol), CuCl2 (0.5 mmol), solvent (3 mL), 110 °C, 2 h. In order to evaluate the practical application value and potential of this reaction system, we carried out a gram-scale amplification experiment under standard reaction conditions (Scheme 3). When the scale of ethylbenzene reached 10 mmol (1.06 g), this transformation proceeded smoothly and imidazo[1,2-a]pyridine 3aa was obtained in 73% yield. Next, we made a bolder attempt, ethylbenzene (2 mmol), styrene (2 mmol) and phenylacetylene (2 mmol) were mixed together to examine this system, and the target product 3aa can also be obtained with good yield. 3ak can also be obtained from this mixed-amplified experiment in 67% yield. This proved it has great value in actual production applications.
Scheme 3

Gram-scale synthesis of 3aa and 3ak. aReaction conditions: 1a (10 mmol), I2 (4 mmol), TBHP (30 mmol), 120 °C, 1 h 10 min then 2-aminopyridine (20 mmol), CuCl2 (5 mmol), solvent (20 mL), 110 °C, 4 h. bReaction conditions: 1a (2 mmol), 3a (2 mmol), 4a (2 mmol), I2 (2.4 mmol), TBHP (18 mmol), 120 °C, 1 h 20 min then 2-aminopyridine (12 mmol), CuCl2 (3 mmol), solvent (10 mL), 110 °C, 2.5 h. cReaction conditions: 1a (2 mmol), 3a (2 mmol), 4a (2 mmol), I2 (2.4 mmol), TBHP (18 mmol), 120 °C, 1 h 20 min then 2k (12 mmol), CuCl2 (3 mmol), solvent (10 mL), 110 °C, 2 h.

In order to carefully explore the process of the mechanism in the reaction, some control experiments were performed (Scheme 4). It was found that ethylbenzene 1a can be converted to acetophenone 1aa under oxidant-promoted conditions.[13]1aa can be confirmed by HRMS and GC-MS. Acetophenone 1aa can further react to obtain α-iodo ketone 1ab under the conditions of I2/TBHP catalysis. 1ab reacted with 2-aminopyridine smoothly to afford product 3aa in 90% yield in CuCl2/DMF conditions (Scheme 4a). α-Iodo ketone 1ab was an important intermediate in the reaction process, which was also obtained from compound 2a and 3a (Scheme 4b). α-Iodo ketone 1ab was easily converted to phenylglyoxal 1ac in DMSO,[14] and further condensed with 2-aminopyridine to form 1ad, which also explained why the yield of 3aa in DMSO was not as good as in DMF during the screening of reaction conditions (Scheme 4c).
Scheme 4

The control experiments.

On the basis of the control experiments described above and reported literature,[15] a possible mechanism for multiple C–H activation followed by circularization cross-coupling is outlined in Scheme 5.
Scheme 5

The proposed reaction mechanism.

Initially, ethylbenzene was initiated by I2/TBHP and underwent benzylic radical of ethylbenzene process to obtain 1-phenyl ethanol (A). Then, 1-phenyl ethanol (A) was converted to acetophenone (1aa) via TBHP oxidation, and 1aa can be confirmed by TLC, HRMS and GC-MS. Acetophenone (1aa) on iodination offered α-iodo acetophenone (1ab). Styrene (3a) and phenylacetylene (4a) can also be converted into this key intermediate (1ab) through the addition of hydroxyl radicals to unsaturated bonds and the catalysis of I2/TBHP. 1ab can be confirmed by TLC and HRMS. α-Iodo acetophenone (1ab) and 2a condensed to obtain intermediate (B). Cu2+ coordinated with the two atoms in the C to activate, and the pair of electrons on the Y atom (Y = N, S) carried out a nucleophilic attack on the C–I bond. I− left and C–Y was built to get intermediate D. The deprotonation of D provided the desired product 3aa.

Conclusions

In conclusion, we have developed a multi pathway, environmentally friendly domino synthesis strategy promoted by I2/TBHP. This strategy is applicable to ethylarenes, ethylenearenes and ethynearenes that can react with 2-aminopyridine, 2-aminothiazole and benzothioamide to obtain the corresponding imidazole or thiazole structure. Its resistance to various substituent groups is also excellent. Its mixed-amplified experiment indicates the potential application in industrial production. Owing to the generality of the reaction, this protocol should be of great utility in organic methodology and industrial application.

Experimental

General information

The Reagents and solvents are commercially purchased and used directly unless otherwise mentioned. All reactions were carried out in a sealed Schlenk tubes and monitored by TLC. Flash column chromatography was performed with silica gel (300–400 mesh). 1H and 13C NMR spectra were recorded on a Bruker Avance 400 instrument (400 MHz for 1H and 101 MHz for 13C NMR spectroscopy). Data were reported as chemical shifts in ppm relative to TMS (0.00 ppm) for 1H and CDCl3 (77.16 ppm) or DMSO-d6 (39.52 ppm) for 13C. HRMS spectra were measured on a Q-TOF instrument in positive-ion mode with an ESI ion source.

General procedure for substrates

Ethyl arenes or ethylene arenes or ethyne arenes (1.0 mmol), I2 (0.40 mmol), tert-butyl hydroperoxide (TBHP, 3.5 mmol, 70%, aq. solution) were placed in a sealed tube equipped with a magnetic stirring bar. These mixtures were stirred and reacted at 120 °C for 1–1.5 h. After disappearance of the reactant monitored by TLC, 2-aminopyridine (2.0 mmol) and CuCl2 (0.5 mmol) in DMF (3 mL) was added to the sealed tube at 110 °C and heated for 2 h. After the reaction, 30 mL of saturated Na2S2O3 solution was added to the reaction solution to quench the remaining iodine. Then the solution was extracted with ethyl acetate (3 × 30 mL), dried over anhydrous Na2SO4. The solid was removed by filtration, and the solution was concentrated under vacuum. The residue was purified through silica gel eluting with ethyl acetate/hexanes to give the product.

Characterization data for the products

2-Phenylimidazo[1,2-a]pyridine (3aa)

White solid was obtained in 82% isolated yield, mp = 135–137 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.53 (dt, J = 6.8, 1.2 Hz, 1H), 8.40 (s, 1H), 8.02–7.94 (m, 2H), 7.59 (dd, J = 9.1, 1.0 Hz, 1H), 7.45 (t, J = 7.6 Hz, 2H), 7.37–7.29 (m, 1H), 7.25 (ddd, J = 9.1, 6.7, 1.3 Hz, 1H), 6.90 (td, J = 6.7, 1.2 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 145.29, 144.82, 134.39, 129.18, 128.17, 127.35, 126.04, 124.99, 117.11, 112.74, 109.57. HRMS m/z (ESI) calcd for [C13H10N2 + H]+: 195.0917 found: 195.0911.

2-(o-Tolyl)imidazo[1,2-a]pyridine (3ba)

White solid was obtained in 64% isolated yield, mp = 101–103 °C. 1H NMR (400 MHz, CDCl3) δ 6.68 (d, J = 6.8 Hz, 1H), 6.47 (d, J = 6.7 Hz, 1H), 6.40–6.10 (m, 2H), 5.83 (s, 3H), 5.80–5.59 (m, 1H), 5.33 (t, J = 6.7 Hz, 1H), 1.11 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 145.24, 144.65, 135.77, 133.22, 130.92, 129.73, 127.81, 126.04, 125.57, 124.66, 117.51, 112.33, 110.78, 22.66. HRMS m/z (ESI) calcd for [C14H12N2 + H]+: 209.1079 found: 209.1078.

2-(p-Tolyl)imidazo[1,2-a]pyridine (3ca)

White solid was obtained in 85% isolated yield, mp = 144–145 °C. 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 6.7 Hz, 1H), 7.83 (d, J = 8.2 Hz, 2H), 7.75 (s, 1H), 7.60 (d, J = 9.1 Hz, 1H), 7.23 (d, J = 7.9 Hz, 2H), 7.11 (ddd, J = 9.1, 6.8, 1.3 Hz, 1H), 6.69 (td, J = 6.7, 1.2 Hz, 1H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 145.85, 145.59, 137.79, 130.95, 129.45, 125.93, 125.55, 124.52, 117.37, 112.28, 107.80, 21.33. HRMS m/z (ESI): calcd for [C14H12N2 + H]+: 209.1079 found: 209.1079.

2-(4-Chlorophenyl)imidazo[1,2-a]pyridine (3da)

White solid was obtained in 84% isolated yield, mp = 202–205 °C. 1H NMR (400 MHz, CDCl3) δ 8.10–7.91 (m, 2H), 7.80–7.70 (m, 2H), 7.53 (d, J = 9.1 Hz, 1H), 7.35 (d, J = 8.9 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 7.13–7.05 (m, 1H), 6.69 (t, J = 6.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 144.65, 143.58, 132.68, 131.18, 127.89, 126.23, 124.59, 123.98, 116.52, 111.64, 107.16. HRMS m/z (ESI): calcd for [C13H9ClN2 + H]+: 229.0533 found: 229.0524.

2-(4-Fluorophenyl)imidazo[1,2-a]pyridine (3ea)

White solid was obtained in 78% isolated yield, mp = 163–165 °C. 1H NMR (600 MHz, DMSO-d6) δ 9.25–9.21 (m, 1H), 8.77 (s, 1H), 8.02–7.94 (m, 4H), 7.61 (dd, J = 8.4, 6.9 Hz, 2H), 7.58–7.52 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ 138.85, 136.65, 132.35, 129.78, 128.88, 128.68, 126.32, 126.28, 125.66, 122.61, 112.98, 110.77. HRMS m/z (ESI): calcd for [C13H9FN2 + H]+: 213.0829 found: 213.0813.

2-(Naphthalen-1-yl)imidazo[1,2-a]pyridine (3fa)

White solid was obtained in 91% isolated yield, mp = 158–160 °C. 1H NMR (600 MHz, CDCl3) δ 8.46 (dd, J = 1.7, 0.8 Hz, 1H), 8.07 (dt, J = 6.8, 1.2 Hz, 1H), 7.93 (dd, J = 8.5, 1.7 Hz, 1H), 7.90 (d, J = 0.7 Hz, 1H), 7.88–7.84 (m, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.80–7.74 (m, 1H), 7.64 (dq, J = 9.1, 1.0 Hz, 1H), 7.46–7.37 (m, 2H), 7.14 (ddd, J = 9.1, 6.7, 1.3 Hz, 1H), 6.73 (td, J = 6.7, 1.2 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 145.54, 145.27, 133.73, 133.29, 130.51, 128.43, 128.39, 127.72, 126.35, 126.09, 125.70, 125.29, 124.96, 124.10, 117.36, 112.80, 108.60. HRMS m/z (ESI): calcd for [C17H12N2 + H]+: 245.1079 found: 245.1060.

2,3-Diphenylimidazo[1,2-a]pyridine (3ga)

White solid was obtained in 43% isolated yield, mp = 149–151 °C. 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 6.9 Hz, 1H), 7.68 (t, J = 7.7 Hz, 3H), 7.57–7.40 (m, 5H), 7.34–7.14 (m, 4H), 6.72 (t, J = 6.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 144.78, 142.33, 134.11, 130.74, 129.84, 129.58, 128.93, 128.30, 128.12, 127.52, 124.78, 123.31, 121.10, 117.53, 112.34. HRMS m/z (ESI): calcd for [C19H14N2 + H]+: 271.1236 found: 271.1231.

2-(4-(Methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (3ha)

White solid was obtained in 73% isolated yield, mp = 242–244 °C. 1H NMR (400 MHz, CDCl3) δ 8.21–8.13 (m, 3H), 8.05–7.96 (m, 3H), 7.67 (d, J = 9.2 Hz, 1H), 7.25 (ddd, J = 9.1, 6.7, 1.3 Hz, 1H), 6.85 (td, J = 6.8, 1.2 Hz, 1H), 3.11 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 145.98, 143.57, 139.28, 139.26, 127.94, 126.60, 125.86, 125.57, 117.87, 113.11, 109.69, 44.64. HRMS m/z (ESI): calcd for [C14H12N2O2S + H]+: 273.0698 found: 273.0680.

2-(4-Methoxyphenyl)imidazo[1,2-a]pyridine (3ia)

White solid was obtained in 89% isolated yield, mp = 133–135 °C. 1H NMR (600 MHz, CDCl3) δ 7.95 (dq, J = 6.7, 1.1 Hz, 1H), 7.81–7.76 (m, 2H), 7.65–7.61 (m, 1H), 7.51 (dt, J = 9.1, 1.1 Hz, 1H), 7.03 (ddt, J = 9.2, 6.7, 1.3 Hz, 1H), 6.90–6.84 (m, 2H), 6.62 (tt, J = 6.7, 1.4 Hz, 1H), 3.74 (d, J = 1.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 159.61, 145.63, 145.57, 127.31, 126.44, 125.49, 124.50, 117.20, 114.15, 112.25, 107.26, 55.31. HRMS m/z (ESI): calcd for [C14H12N2O + H]+: 225.1029 found: 225.1029.

2-(4-(Trifluoromethyl)phenyl)imidazo[1,2-a]pyridine (3ja)

White solid was obtained in 87% isolated yield, mp = 196–198 °C. 1H NMR (400 MHz, CDCl3) δ 6.68–6.56 (m, 3H), 6.44 (s, 1H), 6.20 (d, J = 8.2 Hz, 3H), 5.76 (dd, J = 15.4, 8.7 Hz, 1H), 5.34 (d, J = 6.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 145.65, 143.91, 136.91, 129.97, 129.64, 126.16, 125.75 (q, J = 4.4 Hz), 125.54, 122.90, 117.62, 113.05, 109.05. HRMS m/z (ESI): calcd for [C14H9F3N2 + H]+: 263.0797 found: 263.0794.

2-(4-Nitrophenyl)imidazo[1,2-a]pyridine (3ka)

Yellow solid was obtained in 85% isolated yield, mp = 258–261 °C. 1H NMR (600 MHz, DMSO-d6) δ 8.65 (d, J = 0.7 Hz, 1H), 8.58 (dt, J = 6.8, 1.3 Hz, 1H), 8.34–8.29 (m, 2H), 8.26–8.21 (m, 2H), 7.63 (dt, J = 9.1, 1.0 Hz, 1H), 7.31 (ddd, J = 9.1, 6.7, 1.3 Hz, 1H), 6.96 (td, J = 6.8, 1.2 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 146.96, 145.73, 142.47, 140.99, 127.74, 126.78, 126.40, 124.67, 117.47, 113.41, 112.17. HRMS m/z (ESI): calcd for [C13H9N3O2 + H]+: 240.0774 found: 240.0766.

2-(Furan-2-yl)imidazo[1,2-a]pyridine (3la)

White solid was obtained in 81% isolated yield, mp = 88–90 °C. 1H NMR (400 MHz, CDCl3) δ 7.98 (dt, J = 6.8, 1.3 Hz, 1H), 7.68 (s, 1H), 7.50 (d, J = 9.0 Hz, 1H), 7.38 (d, J = 1.1 Hz, 1H), 7.07 (ddd, J = 9.2, 6.8, 1.3 Hz, 1H), 6.81 (d, J = 2.6 Hz, 1H), 6.66 (td, J = 6.8, 1.2 Hz, 1H), 6.42 (dd, J = 3.4, 1.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 148.57, 144.53, 141.02, 136.88, 124.63, 123.95, 116.30, 111.49, 110.56, 106.83, 105.65. HRMS m/z (ESI): calcd for [C11H8N2O + H]+: 185.0716 found: 185.0696.

2-(Thiophen-2-yl)imidazo[1,2-a]pyridine (3ma)

White solid was obtained in 76% isolated yield, mp = 136–138 °C. 1H NMR (600 MHz, CDCl3) δ 7.84 (dt, J = 6.7, 1.2 Hz, 1H), 7.54 (d, J = 0.7 Hz, 1H), 7.44 (dq, J = 9.1, 1.0 Hz, 1H), 7.31 (dd, J = 3.6, 1.2 Hz, 1H), 7.16 (dd, J = 5.0, 1.2 Hz, 1H), 6.99–6.91 (m, 2H), 6.55 (td, J = 6.7, 1.2 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 145.35, 140.71, 137.55, 127.78, 125.50, 125.02, 124.86, 123.69, 117.10, 112.51, 107.50. HRMS m/z (ESI): calcd for [C11H8N2S + H]+: 201.0487 found: 201.0468.

2-(3-Chlorophenyl)imidazo[1,2-a]pyridine (3na)

White solid was obtained in 62% isolated yield, mp = 107–109 °C. 1H NMR (600 MHz, CDCl3) δ 8.05 (dt, J = 6.8, 1.2 Hz, 1H), 7.89 (t, J = 1.9 Hz, 1H), 7.78 (d, J = 0.7 Hz, 1H), 7.76 (dt, J = 7.7, 1.4 Hz, 1H), 7.58 (dq, J = 9.1, 1.0 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.22 (dd, J = 7.9, 2.1, 1.1 Hz, 1H), 7.13 (dd, J = 9.1, 6.7, 1.3 Hz, 1H), 6.74 (td, J = 6.7, 1.2 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 145.55, 144.14, 135.33, 134.79, 130.03, 128.03, 126.13, 125.73, 125.30, 124.14, 117.55, 112.89, 108.55. HRMS m/z (ESI): calcd for [C13H9ClN2 + H]+: 229.0533 found: 229.0516.

2-(5-Bromothiophen-2-yl)imidazo[1,2-a]pyridine (3oa)

White solid was obtained in 68% isolated yield, mp = 140–142 °C. 1H NMR (400 MHz, CDCl3) δ 6.60 (d, J = 6.8 Hz, 1H), 6.38–6.08 (m, 2H), 5.89–5.69 (m, 2H), 5.55 (d, J = 3.8 Hz, 1H), 5.33 (t, J = 6.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 145.14, 139.49, 138.49, 137.85, 130.72, 125.61, 124.23, 117.16, 113.09, 112.16, 107.42. HRMS m/z (ESI): calcd for [C11H7BrN2S + H]+: 278.9592 found: 278.9573.

2-(2-(Trifluoromethyl)phenyl)imidazo[1,2-a]pyridine (3pa)

White solid was obtained in 43% isolated yield, mp = 90–92 °C. 1H NMR (400 MHz, CDCl3) δ 8.05 (dt, J = 6.8, 1.2 Hz, 1H), 7.91 (d, J = 7.4 Hz, 1H), 7.73 (s, 1H), 7.68 (d, J = 6.6 Hz, 1H), 7.59–7.52 (m, 2H), 7.38 (t, J = 7.7 Hz, 1H), 7.11 (dd, J = 9.1, 6.8, 1.3 Hz, 1H), 6.72 (td, J = 6.8, 1.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 143.72, 141.27, 132.25, 131.55, 130.72, 126.78, 126.45, 125.05(q, J = 5.8 Hz), 124.68, 123.89, 121.96, 116.67, 111.58, 110.41. HRMS m/z (ESI): calcd for [C14H9F3N2 + H]+: 263.0797 found: 263.0796.

2-(2-Fluorophenyl)imidazo[1,2-a]pyridine (3qa)

White solid was obtained in 67% isolated yield, mp = 94–97 °C. 1H NMR (400 MHz, CDCl3) δ 8.29 (td, J = 7.6, 2.7 Hz, 1H), 8.04 (dt, J = 6.8, 1.2 Hz, 1H), 7.97 (d, J = 3.9 Hz, 1H), 7.56 (dd, J = 9.1, 1.0 Hz, 1H), 7.27–7.15 (m, 2H), 7.13–7.03 (m, 2H), 6.70 (td, J = 6.8, 1.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 160.51, 158.04, 143.77, 138.07, 127.85 (J = 8.6 Hz), 124.71, 123.98, 123.47 (J = 3.3 Hz), 120.42 (J = 12.2 Hz), 116.39, 114.62 (J = 22.1 Hz), 111.46, 111.06 (J = 15.2 Hz). HRMS m/z (ESI): calcd for [C13H9FN2 + H]+: 213.0829 found: 213.0826.

2-(3-Fluorophenyl)imidazo[1,2-a]pyridine (3ra)

White solid was obtained in 65% isolated yield, mp = 101–103 °C. 1H NMR (400 MHz, CDCl3) δ 8.09 (dt, J = 6.8, 1.2 Hz, 1H), 7.83 (s, 1H), 7.77–7.57 (m, 3H), 7.38 (td, J = 8.0, 5.9 Hz, 1H), 7.17 (dd, J = 9.1, 6.8, 1.3 Hz, 1H), 7.01 (tdd, J = 8.4, 2.7, 1.0 Hz, 1H), 6.78 (td, J = 6.8, 1.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 164.49, 162.05, 145.65, 144.56 (J = 2.8 Hz), 136.06 (J = 8.3 Hz), 130.21 (J = 8.3 Hz), 125.66, 125.01, 121.58 (J = 2.9 Hz), 117.61, 114.71 (J = 21.4 Hz), 112.80 (J = 22.1 Hz), 108.54. HRMS m/z (ESI): calcd for [C13H9FN2 + H]+: 213.0829 found: 213.081.

6-Methyl-2-phenylimidazo[1,2-a]pyridine (3ab)

White solid was obtained in 74% isolated yield, mp = 176–177 °C. 1H NMR (600 MHz, CDCl3) δ 7.89–7.84 (m, 2H), 7.81 (dq, J = 2.1, 1.1 Hz, 1H), 7.68 (d, J = 0.7 Hz, 1H), 7.47 (d, J = 9.1 Hz, 1H), 7.38–7.32 (m, 2H), 7.27–7.21 (m, 1H), 6.94 (dd, J = 9.2, 1.7 Hz, 1H), 2.23 (d, J = 1.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 145.30, 144.63, 133.71, 128.72, 128.03, 127.89, 125.96, 123.35, 122.19, 116.76, 107.86, 18.12. HRMS m/z (ESI): calcd for [C14H12N2 + H]+: 209.1079 found: 209.1074.

2-Phenyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine (3ac)

White solid was obtained in 67% isolated yield, mp = 165–166 °C. 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 7.88 (dd, J = 9.8, 1.6 Hz, 3H), 7.66 (d, J = 9.5 Hz, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.33–7.22 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 146.69, 144.26, 131.81, 127.86, 127.63, 125.21, 123.55 (q, J = 5.9 Hz), 121.15, 119.61 (q, J = 2.7 Hz), 117.10, 115.74, 108.19. HRMS m/z (ESI): calcd for [C14H9F3N2 + H]+: 263.0797 found: 263.0794.

2-Phenylimidazo[2,1-a]isoquinoline (3ad)

White solid was obtained in 62% isolated yield, mp = 144–146 °C. 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = 7.9 Hz, 1H), 8.01 (d, J = 6.8 Hz, 2H), 7.86 (d, J = 7.2 Hz, 1H), 7.79 (s, 1H), 7.70–7.60 (m, 2H), 7.59–7.52 (m, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.00 (d, J = 7.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 143.97, 143.28, 133.95, 129.51, 128.76, 128.20, 128.15, 127.65, 126.97, 125.89, 123.80, 123.55, 122.97, 113.17, 109.88. HRMS m/z (ESI): calcd for [C17H12N2 + H]+: 245.1079 found: 245.1072.

6-Chloro-2-phenylimidazo[1,2-a]pyridine (3ae)

White solid was obtained in 63% isolated yield, mp = 206–209 °C. 1H NMR (600 MHz, DMSO-d6) δ 9.25–9.21 (m, 1H), 8.77 (s, 1H), 8.02–7.98 (m, 3H), 7.96 (dd, J = 9.5, 1.9 Hz, 1H), 7.61 (dd, J = 8.4, 6.9 Hz, 2H), 7.58–7.52 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ 138.85, 136.65, 132.35, 129.78, 128.88, 126.32, 126.28, 125.66, 122.61, 112.98, 110.77. HRMS m/z (ESI): calcd for [C13H9ClN2 + H]+: 229.0533 found: 229.0525.

6-Fluoro-2-phenylimidazo[1,2-a]pyridine (3af)

White solid was obtained in 75% isolated yield, mp = 186–189 °C. 1H NMR (400 MHz, CDCl3) δ 7.97–7.90 (m, 1H), 7.83 (d, J = 6.9 Hz, 2H), 7.74 (s, 1H), 7.56 (dd, J = 9.8, 5.1 Hz, 1H), 7.41–7.17 (m, 3H), 7.00 (dd, J = 10.2, 8.0, 2.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 152.27 (J = 237 Hz), 151.10, 145.83, 142.27, 132.16, 127.77, 127.21, 124.97, 116.25 (J = 118 Hz), 111.18 (J = 41 Hz), 108.49. HRMS m/z (ESI): calcd for [C13H9FN2 + H]+: 213.0829 found: 213.0830.

6-Bromo-2-phenylimidazo[1,2-a]pyridine (3ag)

White solid was obtained in 68% isolated yield, mp = 184–186 °C. 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.86 (d, J = 7.0 Hz, 2H), 7.75 (s, 1H), 7.49 (d, J = 9.6 Hz, 1H), 7.37 (t, J = 8.0 Hz, 2H), 7.28 (t, J = 7.4 Hz, 1H), 7.17 (dd, J = 9.5, 1.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 145.31, 142.88, 131.86, 127.81, 127.40, 127.34, 125.08, 123.41, 116.98, 107.25, 106.53. HRMS m/z (ESI): calcd for [C13H9BrN2 + H]+: 273.0028 found: 273.0031.

7-Bromo-2-phenylimidazo[1,2-a]pyridine (3ah)

White solid was obtained in 63% isolated yield, mp = 180–182 °C. 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 7.4 Hz, 1H), 7.89–7.83 (m, 2H), 7.77 (d, J = 3.7 Hz, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.32–7.17 (m, 1H), 6.83 (dd, J = 7.1, 1.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 145.20, 144.52, 131.81, 127.81, 127.40, 125.08, 124.75, 118.57, 117.63, 115.56, 107.26. HRMS m/z (ESI): calcd for [C13H9BrN2 + H]+: 273.0028 found: 273.0030.

6-Nitro-2-phenylimidazo[1,2-a]pyridine (3ai)

Yellow solid was obtained in 57% isolated yield, mp = 171–173 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.84 (d, J = 2.3 Hz, 1H), 8.63 (s, 1H), 8.01 (d, J = 6.9 Hz, 2H), 7.96 (dd, J = 9.9, 2.3 Hz, 1H), 7.75 (d, J = 9.9 Hz, 1H), 7.54–7.45 (m, 2H), 7.40 (t, J = 7.3 Hz, 1H) 13C NMR (101 MHz, DMSO-d6) δ 147.91, 145.46, 136.97, 133.16, 129.44, 129.15, 128.55, 126.40, 119.54, 116.52, 112.16. HRMS m/z (ESI): calcd for [C13H9N3O2 + H]+: 240.0774 found: 240.0769.

4-Phenylthiazol-2-amine (3aj)

White solid was obtained in 79% isolated yield, mp = 147–149 °C. 1H NMR (400 MHz, CDCl3) δ 7.73–7.65 (m, 2H), 7.31 (dd, J = 8.3, 6.7 Hz, 2H), 7.26–7.16 (m, 1H), 6.64 (s, 1H), 5.22 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 166.42, 150.10, 133.53, 127.58, 126.73, 124.95, 101.70. HRMS m/z (ESI): calcd for [C9H8N2S + H]+: 177.0487 found: 177.0479.

2,4-Diphenylthiazole (3ak)

White solid was obtained in 86% isolated yield, mp = 101–104 °C. 1H NMR (400 MHz, CDCl3) δ 8.00–7.89 (m, 4H), 7.36 (m, J = 7.9, 5.8 Hz, 6H), 7.30–7.24 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 167.90, 156.31, 134.55, 133.79, 130.08, 128.96, 128.78, 128.21, 126.65, 126.49, 112.66. HRMS m/z (ESI): calcd for [C15H11NS + H]+: 238.0688 found: 238.0680.

2-Phenylbenzo[d]imidazo[2,1-b]thiazole (3al)

White solid was obtained in 82% isolated yield, mp = 142–146 °C. 1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.79 (d, J = 7.0 Hz, 2H), 7.60 (d, J = 8.1 Hz, 1H), 7.50 (d, J = 9.2 Hz, 1H), 7.39–7.29 (m, 3H), 7.28–7.15 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 147.03, 146.57, 132.74, 131.08, 129.21, 127.69, 126.48, 125.14, 124.13, 123.82, 123.33, 111.59, 105.81. HRMS m/z (ESI): calcd for [C15H10N2S + H]+: 251.0644 found: 251.0639.

Methyl 2-phenylimidazo[1,2-a]pyridine-6-carboxylate (3am)

White solid was obtained in 55% isolated yield, mp = 174–175 °C. 1H NMR (400 MHz, CDCl3) δ 8.81 (dd, J = 1.7, 1.0 Hz, 1H), 7.92–7.85 (m, 2H), 7.83 (s, 1H), 7.64 (dd, J = 9.4, 1.7 Hz, 1H), 7.55 (d, J = 9.4 Hz, 1H), 7.37 (dd, J = 8.2, 6.7 Hz, 2H), 7.32–7.25 (m, 1H), 3.88 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 164.27, 146.53, 145.04, 131.96, 128.74, 127.80, 127.50, 125.17, 123.38, 115.66, 115.48, 107.91, 51.43. HRMS m/z (ESI): calcd for [C15H12N2O2 + H]+: 253.0978 found: 253.0976.

6-Methoxy-2-phenylimidazo[1,2-a]pyridine (3an)

White solid was obtained in 81% isolated yield, mp = 102–105 °C. 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 7.1 Hz, 2H), 7.73 (s, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.47 (d, J = 9.8 Hz, 1H), 7.36 (t, J = 7.7 Hz, 2H), 7.21 (d, J = 14.2 Hz, 1H), 6.90 (dd, J = 9.7, 2.4 Hz, 1H), 3.75 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 148.36, 141.59, 132.57, 129.90, 127.71, 126.82, 124.77, 119.04, 116.53, 108.17, 106.40, 55.15. HRMS m/z (ESI): calcd for [C14H12N2O + H]+: 225.1029 found: 225.1034.

2-Phenylimidazo[1,2-a]pyridine-6-carbonitrile (3ao)

White solid was obtained in 51% isolated yield, mp = 240–243 °C. 1H NMR (600 MHz, CDCl3) δ 8.50 (t, J = 1.3 Hz, 1H), 7.92–7.86 (m, 3H), 7.65 (d, J = 9.3 Hz, 1H), 7.40 (dd, J = 8.4, 6.9 Hz, 2H), 7.35–7.29 (m, 1H), 7.22 (dd, J = 9.3, 1.7 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 148.21, 144.69, 132.26, 131.52, 129.06, 128.99, 126.38, 124.72, 118.39, 116.47, 108.97, 98.83. HRMS m/z (ESI): calcd for [C14H9N3 + H]+: 220.0875 found: 220.0869.

2,6-Diphenylimidazo[1,2-a]pyridine (3ap)

White solid was obtained in 66% isolated yield, mp = 178–180 °C. 1H NMR (400 MHz, CDCl3) δ 9.98 (s, 1H), 9.77 (s, 1H), 9.26 (d, J = 10.6 Hz, 1H), 8.50–8.16 (m, 5H), 7.75–6.94 (m, 5H), 6.86 (d, J = 8.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 161.99, 158.51, 150.01, 149.93, 147.54, 146.39, 137.89, 137.69, 119.19, 118.82, 114.11, 109.50. HRMS m/z (ESI): calcd for [C19H14N2 + H]+: 271.1236 found: 271.1243.

Conflicts of interest

There are no conflicts to declare.
  25 in total

1.  Imidazo[1,2-a]pyridines susceptible to excited state intramolecular proton transfer: one-pot synthesis via an Ortoleva-King reaction.

Authors:  Anton J Stasyuk; Marzena Banasiewicz; Michał K Cyrański; Daniel T Gryko
Journal:  J Org Chem       Date:  2012-06-11       Impact factor: 4.354

2.  Response to "Prevention of CS 'tear gas' eye and skin effects and active decontamination with diphoterine: preliminary studies in 5 French Gendarmes".

Authors:  Annie Luka; Andrew Stolbach; Robert S Hoffman
Journal:  J Emerg Med       Date:  2007-02-27       Impact factor: 1.484

3.  Heteroaromatic imidazo[1,2-a]pyridines synthesis from C-H/N-H oxidative cross-coupling/cyclization.

Authors:  Chuan He; Jing Hao; Huan Xu; Yiping Mo; Huiying Liu; Juanjuan Han; Aiwen Lei
Journal:  Chem Commun (Camb)       Date:  2012-09-27       Impact factor: 6.222

4.  Rare and Severe Maxillofacial Injury Due to Tear Gas Capsules: Report of Three Cases.

Authors:  Şeref Kerem Çorbacɩoğlu; Sertaç Güler; Erhan Er; Meltem Seviner; Şahin Aslan; Gökhan Aksel
Journal:  J Forensic Sci       Date:  2015-09-16       Impact factor: 1.832

5.  Arylruthenium(III) Porphyrin-Catalyzed C-H Oxidation and Epoxidation at Room Temperature and [RuV(Por)(O)(Ph)] Intermediate by Spectroscopic Analysis and Density Functional Theory Calculations.

Authors:  Ka-Pan Shing; Bei Cao; Yungen Liu; Hung Kay Lee; Ming-De Li; David Lee Phillips; Xiao-Yong Chang; Chi-Ming Che
Journal:  J Am Chem Soc       Date:  2018-05-21       Impact factor: 15.419

6.  An outstanding catalyst for the oxygen-mediated oxidation of arylcarbinols, arylmethylene and arylacetylene compounds.

Authors:  G Urgoitia; R SanMartin; M T Herrero; E Domínguez
Journal:  Chem Commun (Camb)       Date:  2015-03-21       Impact factor: 6.222

7.  Copper(II)/iron(III) co-catalyzed intermolecular diamination of alkynes: facile synthesis of imidazopyridines.

Authors:  Jing Zeng; Yu Jia Tan; Min Li Leow; Xue-Wei Liu
Journal:  Org Lett       Date:  2012-08-10       Impact factor: 6.005

8.  A multipathway coupled domino strategy: metal-free oxidative cyclization for one-pot synthesis of 2-acylbenzothiazoles from multiform substrates.

Authors:  Yan-ping Zhu; Feng-cheng Jia; Mei-cai Liu; An-xin Wu
Journal:  Org Lett       Date:  2012-08-27       Impact factor: 6.005

Review 9.  Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects.

Authors:  Katsufumi Mizushige; Takashi Ueda; Kazushi Yukiiri; Hitoshi Suzuki
Journal:  Cardiovasc Drug Rev       Date:  2002

10.  Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts.

Authors:  Naresh Gunaganti; Anupreet Kharbanda; Naga Rajiv Lakkaniga; Lingtian Zhang; Rose Cooper; Hong-Yu Li; Brendan Frett
Journal:  Chem Commun (Camb)       Date:  2018-11-15       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.